As the number of public companies has significantly declined, and public markets have proved increasingly unwilling or unable to nurture the bold idea or the risky turnaround, private capital has picked up the ball and run with it. Much of the explosive growth in the number and variety of private companies has been fueled by private equity, which is currently approaching $5T in global assets under management.
As PE has taken off, it has evolved and differentiated. Each firm’s approach to governance and management drives strategy and behavior in distinctive ways. They vary in their philosophies and bring unique skills and resources to their deals. Whether you are an owner-operator of a private business looking to sell or take some “chips” off the table or a seasoned executive looking to partner with a PE investor to manage or acquire a business, these distinctions are important to consider.
Join fellow CEOs and this highly experienced, expert panel for a discussion of what different PE firms bring to the table, how they operate, what contributions PE firms, in general, are expecting from their equity partners and management teams, and how to work together towards a mutually rewarding exit.
10-11 am ET
9-10 am CT
8-9 am MT
7-8 am PT
Murtaza Ali, Operating Partner, Hawthorne
Murtaza joined Davidson Kempner in February 2020. Previously, he worked as a Senior Operating Partner at BlueMountain Capital Management. Prior to BlueMountain, Murtaza was Co-Founder at Blue Top Capital and a Managing Director at Anchorage Capital, working on Anchorage's value creation efforts across a range of industries including real estate, healthcare and business services. Previously, Murtaza held various leadership roles at the Boston Consulting Group, Target and McKinsey.
Murtaza received his Bachelor of Science in Chemical Engineering and Master of Business Administration from the University of Pennsylvania.
Kurt Brykman, Board Member at Regulatory & Quality Solutions (R&Q), Lotus Clinical Research and Insight2Profit, Operating Partner, DFW
Kurt is a proven healthcare executive who has built a career on business transformations and turnarounds along with a strong track record of achieving revenue and EBITDA growth. Kurt's expertise spans product, service and consulting businesses in industries ranging from healthcare to consumer products. He has worked with DFW Capital Partners as an Operating Partner starting in 2018 and currently serves as a board member for Lotus Clinical Research, a company which focuses on conducting clinical trials related to acute and chronic pain. He also serves on the Board of Insight2Profit, a service company focused on delivering EBITDA growth for clients through implementation and management of pricing strategies. Lastly, Kurt serves on the board of RQM+, a regulatory and compliance consultancy focused on helping medical device firm bring their products to market.
Prior to working with DFW, Kurt was the CEO of Kinapse, a London based life science company that specializes in worldwide regulatory affairs outsourcing for biopharma companies. Prior to Kinapse, he was the COO of Medpace, a specialty clinical research organization which provides expertise in executing scientifically challenging trials. Prior to that, he spent 9 years as an Officer and divisional President of PAREXEL International, the 3rd largest CRO worldwide, where he successfully ran the PAREXEL Consulting, PAREXEL Medical Communications and PAREXEL Late Phase Clinicals business units.
RJ David, Consumer, Media & Retail Private Equity - The Carlyle Group
RJ is a Principal at The Carlyle Group focusing on both buy-out and growth investments in the Consumer, Media, and Retail sectors. RJ currently sits on the boards of Array Marketing Services, Every Man Jack, and Service King.
Prior to joining Carlyle in 2016, RJ spent nearly 10 years at Platinum Equity in Los Angeles where he focused on M&A execution and deal origination.
RJ began his career as an Investment Banking Analyst for Houlihan Lokey. He received his Bachelor of Science degree in Business Administration from the University of Southern California.
Marc Hodak, Partner at Farient Advisors LLC, Governance Expert, Compensation Advisor, Independent Director, Speaker, Author, Professor
During Marc's more than 20 years of experience as a compensation consultant, he has developed executive and board compensation programs for global companies, both private and public. His expertise extends across multiple industries which include manufacturing, consumer products, energy, financial services, real estate, technology, telecommunications and transportation.
Marc works closely with senior management, boards of directors, and investors, in both public and private companies, to develop executive compensation programs that are shareholder-friendly, attractive to management, and responsive to the needs and concerns of Boards. He is a recognized thought leader in incentive plan design, and has been published in numerous magazines including Forbes, NACD/Directorship, Directors & Boards, as well as in academic journals. Marc has taught corporate governance as a professor at NYU’s Stern School and as a visiting lecturer at the University of St. Gallen in Switzerland for over ten years. He has been quoted in the national press, including the Wall Street Journal, Bloomberg, and Reuters, and is a sought after speaker at forums and conferences throughout the U.S. and Europe on executive compensation, corporate governance, and managing for value. Marc is a 2020 honoree of the NACD Directorship 100.
Marc earned his MBA in Finance at the Wharton School following a Bachelor of Science in Aerospace Engineering at the University of Maryland.